Dermaheal Effect on Diabetic Foot Ulcer

Phase 3

• Conditions: Diabetic Foot Ulcer.; Type 2 diabetes mellitus with neurological complications; E11.4

• Registration Number: IRCT20080904001199N4
• Lead Sponsor: Darudarman Salafchegan Co. (Knowledge-based)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Wagner G 1&2 Diabetic Foot Ulcer
Neuropathic and Neuroischemin Ulcer 0.7 = ABI = 1.2

Exclusion Criteria

Patient Disagreement to Participate
Use of Medications that can Interfere with Wound Healing such as Corticosteroids, Immunosuppressive agents, and Cytotoxic agents

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
lcer Area. Timepoint: End of every week. Method of measurement: Images & and ruler.;Wound Discharge. Timepoint: End of every week. Method of measurement: Color, odor and amount by wound healing checklist.;Surrounding tissues. Timepoint: End of every week. Method of measurement: Color, hotness, edema and sense by wound healing checklist.

Secondary Outcome Measures

Name	Time	Method
ABI. Timepoint: End of treatment. Method of measurement: ABI measurement Device.;FBS. Timepoint: End of treatment. Method of measurement: Glucometer.;Pain severity. Timepoint: End of every week. Method of measurement: Visual pain scale.